Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers boosted its stake in Arvinas, Inc. (NASDAQ:ARVN) by 0.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 87,877 shares of the company’s stock after acquiring an additional 754 shares during the quarter. Rhumbline Advisers’ holdings in Arvinas were worth $1,685,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KBC Group NV lifted its holdings in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after purchasing an additional 440 shares during the last quarter. Quantbot Technologies LP lifted its stake in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after buying an additional 2,601 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Arvinas by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after buying an additional 1,367 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Arvinas during the 3rd quarter worth approximately $350,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Price Performance

Shares of ARVN stock opened at $16.52 on Wednesday. The company has a market capitalization of $1.14 billion, a PE ratio of -5.96 and a beta of 1.95. The firm’s 50-day moving average is $18.32 and its two-hundred day moving average is $22.59. Arvinas, Inc. has a 12 month low of $15.53 and a 12 month high of $49.76.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the firm posted ($2.53) EPS. Sell-side analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ARVN. BMO Capital Markets restated an “outperform” rating and issued a $82.00 target price (down previously from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. HC Wainwright restated a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a report on Wednesday, December 11th. BTIG Research began coverage on shares of Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price on the stock. Barclays reduced their target price on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Finally, Guggenheim restated a “buy” rating and set a $57.00 price target on shares of Arvinas in a research report on Wednesday, February 12th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $60.00.

Insider Buying and Selling at Arvinas

In related news, CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the transaction, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. The trade was a 5.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,572 shares of company stock worth $695,030 over the last quarter. 5.23% of the stock is currently owned by company insiders.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.